PharmaEngine PharmaEngine
en中文版
  • About Us
    • Overview
    • Business Model
    • Board of Directors
    • Management Team
    • Advisory Boards
    • History & Milestones
  • R & D Pipeline
  • Investors
    • Investor Overview
    • Financial Reports
    • Shareholders’ Meetings
    • Events & Presentations
  • News
  • Careers
  • Contact
  • About Us
    • Overview
    • Business Model
    • Board of Directors
    • Management Team
    • Advisory Boards
    • History & Milestones
  • R & D Pipeline
  • Investors
    • Investor Overview
    • Financial Reports
    • Shareholders’ Meetings
    • Events & Presentations
  • News
  • Careers
  • Contact
Share on TwitterShare on FacebookShare on Google PlusShare on PinterestShare on LinkedInShare on RedditShare on TumblrShare on Xing

Nanobiotix

PharmaEngine > News > Nanobiotix

PharmaEngine Announces Positive Topline Results from Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue Sarcoma

2018/06/21 Uncategorized

PharmaEngine’s Partner, Nanobiotix, Presents First Promising Data from Phase I/II Liver Cancer Trial of PEP503 at ASCO GI

2018/01/23 Uncategorized

PharmaEngine Announces Initiation of Phase 1b/2 Trial of PEP503 (NBTXR3) in Head and Neck Cancer

2016/10/19 Uncategorized

© 2018 PharmaEngine Inc.